4//SEC Filing
Kennedy Eugene P. 4
Accession 0001126234-21-000008
CIK 0001126234other
Filed
Feb 2, 7:00 PM ET
Accepted
Feb 3, 6:51 PM ET
Size
8.5 KB
Accession
0001126234-21-000008
Insider Transaction Report
Form 4
LUMOS PHARMA, INC.(LUMO)
Kennedy Eugene P.
Chief Medical Officer
Transactions
- Award
Stock Option (Right to Buy)
2021-02-01+31,475→ 31,475 totalExercise: $17.35Exp: 2031-01-31→ Common Stock (31,475 underlying) - Award
Common Stock
2021-02-01+939→ 11,423 total
Footnotes (4)
- [F1]Represents shares issued as restricted stock units ("RSUs") under the Issuer's 2009 Equity Incentive Plan, as amended, (the "Plan") that were received as an award, for no consideration. The RSUs vest in a series of four successive annual installments beginning on February 1, 2022, provided in each case that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan.
- [F2]Includes 9,000 RSUs previously reported as holdings of the Reporting Person granted under the Plan. The RSUs will vest, and shares will be delivered to the Reporting Person in a series of four successive annual installments with the next installment occurring on April 1, 2021, provided in each case that the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan.
- [F3]Grant to the Reporting Person of a stock option under the Plan. 21,475 of the options vest and become exercisable in a series of 48 successive equal monthly installments beginning on March 1, 2021, provided that at the relevant vesting dates the Reporting Person's continuous service to the Issuer has not been terminated as defined in or as determined under the Plan.
- [F4]The remaining 10,000 stock options vest and become exercisable as follows: (a) 5,000 of such shares shall vest on the 1st of the month following enrollment reaching 50% of total patients enrolled for the LUM-201 trial, and (b) 5,000 of such shares shall vest on the 1st of the month following completion of the LUM-201 trial, in each case as determined by the Board. The option expires ten years after the date of grant.
Documents
Issuer
LUMOS PHARMA, INC.
CIK 0001126234
Entity typeother
Related Parties
1- filerCIK 0001721685
Filing Metadata
- Form type
- 4
- Filed
- Feb 2, 7:00 PM ET
- Accepted
- Feb 3, 6:51 PM ET
- Size
- 8.5 KB